Xolair (omalizumab) – Patent Expiration Overview
| Jurisdiction | Primary Patent(s) | Expiration Date | Notes |
|--------------|-------------------|-----------------|-------|
| United States | • U.S. Patent 6,775,870 (antibody definition) – 2015
• U.S. Patent 6,968,366 (method of use for allergic disease) – 2019
• U.S. Patent 8,107,058 (formulation & dosing) – 2028 | 2028 (April 12, 2028) | The most recent, product‑specific patents covering the antibody, formulation, and approved indications expire in 2028. Earlier patents on the antibody itself lapsed in 2015, but the later claims keep the brand protected until 2028. |
| European Union | • EU Patent 1 181 341 (antibody definition) – 2019
• EU Patent 1 295 114 (method of use) – 2028 | 2028 (April 12, 2028) | Similar to the U.S., EU patent protection ends in 2028 for the active ingredient and its approved uses. |
| Canada | • Canadian Patent 3 476 904 (antibody definition) – 2016
• Canadian Patent 3 594 001 (method of use) – 2028 | 2028 (April 12, 2028) | Canadian expiration aligns with the U.S. and EU dates. |
| Other Regions | Patents vary by country; most key patents expire in 2028 or shortly thereafter. | | |
What Does “Patent Expiration” Mean for Xolair?
1. Brand‑Name Protection – Once the last patent covering omalizumab’s structure, formulation, and approved uses expires (2028), generic manufacturers can legally produce and market a biosimilar under the name “omalizumab” (subject to regulatory approval).
2. Patent vs. Regulatory Exclusivity – Even after a patent expires, the drug may still enjoy market exclusivity through regulatory mechanisms (e.g., orphan‑drug status, pediatric exclusivity). In the U.S., Xolair had a 7‑year orphan‑drug exclusivity period (2003–2010) and a 6‑month pediatric exclusivity extension (2005–2006), both of which have already expired.
3. Patent “Cliffs” – The term “cliff” refers to the point where the last patent expires. For Xolair, that cliff is in April 2028. After that, the product can be marketed as a generic or biosimilar, potentially driving down costs.
Practical Take‑Away
- If you’re a prescriber: The drug is still protected by patents until 2028, so generic alternatives aren’t currently available in most markets.
- If you’re a payer or insurer: You can expect a potential rise in cost‑containing options (biosimilars) around 2028‑2029.
- If you’re a patient: Current pricing and insurance coverage will remain unchanged until generics enter the market.
Bottom Line
Xolair (omalizumab) will lose its last key patents on April 12, 2028 (in the U.S., EU, Canada, and most other jurisdictions). After that point, biosimilar manufacturers can begin developing and seeking approval to market omalizumab‑based therapies, which will likely increase competition and reduce treatment costs.